Impact of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) on Increased Residual Gastric Content in Patients With and Without Concurrent Colonoscopy: A Retrospective Case–Control Study

Shiyi Chang, Yan Tang, Meng Wang, Shengjun Zhu, Xi Tan, Xiaowei Fan, Ly Lu, Bensong Duan, Li ShenJournal of Clinical Medicine 2026 · DOI

TL;DR

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), widely used for diabetes and obesity, significantly increase the risk of residual gastric content (RGC) during endoscopic procedures, even with standard bowel preparation. This finding is particularly concerning for patients undergoing concurrent colonoscopies, highlighting the need for more stringent preoperative management strategies.

What Problem Does This Paper Address?

GLP-1 RAs have become increasingly popular for managing type 2 diabetes and obesity due to their effectiveness in glycemic control and weight loss. However, a known side effect is delayed gastric emptying, which can lead to increased residual gastric content (RGC) in the stomach. This RGC poses a risk during procedures like esophagogastroduodenoscopy (EGD) and colonoscopy, potentially leading to aspiration or the need to cancel or repeat the procedure. While previous studies have examined RGC in the context of EGD, there's a lack of specific analysis on patients undergoing concurrent colonoscopy, where bowel preparation is also a factor. This paper aims to clarify the impact of GLP-1 RAs on RGC in both EGD alone and EGD with concurrent colonoscopy, especially considering the standard bowel preparation protocols.

Methods

This study employed a retrospective case-control design. Researchers analyzed data from Shanghai East Hospital between January 2023 and June 2025. They identified "cases" as patients with endoscopically confirmed increased RGC and "controls" as patients without RGC, matched at a 1:2 ratio for age and sex. The primary analysis involved multivariable logistic regression to determine the independent association between GLP-1 RA use and increased RGC, while accounting for potential confounding factors. Data on patient demographics, medical conditions, and procedural details were extracted from electronic health records.

Datasets

The study utilized data from the internal endoscopy database of Shanghai East Hospital, encompassing 131,255 procedures performed between January 2023 and June 2025. The final analysis included 3746 patients (1257 with increased RGC and 2489 controls).

Key Insights and Ideas

  • GLP-1 RAs are a potent driver of RGC: The study strongly suggests that GLP-1 RAs are a significant independent risk factor for increased residual gastric content, even when other factors are controlled for.
  • Concurrent colonoscopy doesn't negate the risk: Standard bowel preparation for colonoscopy, which is designed to clear the lower GI tract, does not seem to sufficiently mitigate the gastric-emptying delay caused by GLP-1 RAs. This implies that the issue is primarily in the upper GI tract.
  • Diabetes complications exacerbate the problem: Patients with diabetes complications showed a significantly higher likelihood of increased RGC, suggesting that underlying neuropathy or other diabetes-related issues might worsen the effect of GLP-1 RAs on gastric motility.
  • Aborted procedures are a real consequence: The study found a substantially higher rate of procedure cancellations among patients with increased RGC, underscoring the clinical impact of this finding.
  • Current guidelines might be too liberal: The findings challenge the more relaxed approach recommended by some societies (like the AGA) for patients on GLP-1 RAs who are asymptomatic, suggesting a need for more stringent preoperative assessment.

Key Results

  • Among 131,255 screened procedures, 3746 patients were included in the analysis.
  • GLP-1 RA users had significantly higher odds of increased RGC:
  • Unadjusted OR: 15.20 (95% CI 5.98–38.61)
    • Adjusted OR (aOR): 13.31 (95% CI 5.07–34.93)
  • Diabetes-related complications were also a significant risk factor for RGC (aOR = 8.89, 95% CI 3.15–25.12).
  • In the subgroup of GLP-1 RA users undergoing concurrent colonoscopy (n=22), a striking 86.4% (19 out of 22) exhibited increased RGC. All of these patients also had solid stool during colonoscopy, indicating that the RGC was present despite bowel preparation.
  • Procedures were aborted in 10.02% of patients with increased RGC, compared to 3.87% overall.
  • No aspiration events were reported in the study.

Limitations and Future Work

The authors acknowledge several limitations:

  • Single-center retrospective study: This limits generalizability and introduces potential biases.
  • Relatively small GLP-1 RA cohort: The sample size for GLP-1 RA users was modest, impacting the precision of effect estimates and the ability to conduct more detailed subgroup analyses. A multicenter study is recommended.
  • Electronic medical record data: Reliance on EMRs for medication data might miss prescriptions from external healthcare systems, and the objective measurement of RGC was visual estimation rather than precise gastric volume ultrasound.
  • Potential confounding from other medications: The influence of other medications that affect gastrointestinal motility (e.g., opioids) could not be fully controlled.

Future work should focus on multicenter studies to confirm these findings with larger cohorts. Investigating more objective methods for assessing gastric emptying, such as gastric ultrasound, pre-procedure would be beneficial. The authors also suggest exploring individualized preoperative plans, potentially involving longer fasting periods or the use of prokinetic agents, for high-risk patients.

Summary updated

Abstract

Background/Objectives: The use of GLP-1 RAs has dramatically increased with expanded indications for diabetes mellitus and obesity. Delayed gastric emptying due to these medications can lead to increased residual gastric content (RGC). While previous studies have focused on Esophagogastroduodenoscopy (EGD), few have specifically analyzed the impact of GLP-1 RAs on residual gastric content in patients undergoing concurrent colonoscopy with adequate bowel preparation. Methods: A retrospective, case–control study was conducted at Shanghai East Hospital from January 2023 to June 2025. Adult patients with increased RGC were identified as cases. Controls without increased RGC were randomly selected at a 1:2 ratio, matched for age and sex. Multivariable logistic regression was used to assess the independent association between GLP-1 RAs use and increased RGC. Results: Among 131,255 procedures screened, 3746 patients were included (1257 with increased RGC and 2489 controls). GLP-1 RAs users had higher odds of increased RGC in both unadjusted [OR 15.20 (95% CI 5.98–38.61)] and adjusted analyses [aOR = 13.31 (95% CI 5.07–34.93)]. Other significant risk factors for RGC included diabetes-related complications [aOR = 8.89 (3.15–25.12)]. Interestingly, among the enrolled patients who used GLP-1 RAs and underwent concurrent colonoscopy, 19 of the 22 patients (86.4%) exhibited increased RGC, whereas only 3 (13.6%) did not. Conclusions: Perioperative use of GLP-1 RAs is associated with an increased residual gastric content in patients undergoing EGD alone or with concurrent colonoscopy. There was no aspiration event related to residual gastric content. Our study highlights the need for vigilant preoperative assessment and individualized periprocedural management in patients on GLP-1 RAs undergoing endoscopic procedures, despite having standardized adequate bowel preparation.
BibTeX
@article{chang2026impact,
  author = {Shiyi Chang and Yan Tang and Meng Wang and Shengjun Zhu and Xi Tan and Xiaowei Fan and LY Lu and Bensong Duan and Li Shen},
  title = {{Impact of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) on Increased Residual Gastric Content in Patients With and Without Concurrent Colonoscopy: A Retrospective Case–Control Study}},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  doi = {10.3390/jcm15062121},
}
Figure